目的 探讨云芝菌胶囊联合甘草酸二铵胶囊治疗病毒性肝炎的临床疗效。方法 选取2015年8月—2016年8月在恩施市中心医院接受治疗的病毒性肝炎患者86例，根据治疗方案的差别分为对照组（43例）和治疗组（43例）。对照组口服甘草酸二铵胶囊，3粒/次，3次/d。治疗组在对照组基础上口服云芝菌胶囊，3粒/次，3次/d。两组患者均治疗3个月。比较两组患者治疗前后临床疗效、肝功能、生活质量评分和肝纤维化指标差异。结果 治疗后，对照组和治疗组的总有效率分别为81.40%、95.35%，两组总有效率比较差异具有统计学意义（P< 0.05）。治疗后，两组血清丙氨酸氨基转移酶（ALT）、天门冬氨酸转氨酶（AST）和总胆红素（TBIL）水平显著降低，凝血酶原活动度（PTA）水平显著升高，同组比较差异具有统计学意义（P< 0.05）；且治疗组上述肝功能指标显著优于对照组（P< 0.05）。治疗后，两组患者躯体功能、心理功能、社会功能和物质生活评分均比同组治疗前明显升高（P< 0.05）；且治疗组生活质量评分升高的更显著（P< 0.05）。治疗后，两组患者血清透明质酸（HA）、层黏连蛋白（LN）、Ⅲ型前胶原肽（PC-III）和Ⅳ型胶原（IV-C）均比同组治疗前明显降低（P< 0.05）；且治疗组患者降低程度显著优于对照组（P< 0.05）。结论 云芝菌胶囊联合甘草酸二铵胶囊治疗病毒性肝炎效果显著，可明显改善患者生活质量、肝功能及肝纤维化指标，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Yunzhijun Capsules combined with Diammonium Glycyrrhizinate Capsules in treatment of viral hepatitis. Methods Patients (86 cases) with viral hepatitis in Enshi Central Hospital from August 2015 to August 2016 were divided into control (43 cases) and treatment (43 cases) groups based on different treatment. Patients in the control group were po administered with Diammonium Glycyrrhizinate Capsules, three grains/time, three times daily. Patients in the treatment group were po administered with Yunzhijun Capsules on the basis of the control group, three grains/time, three times daily. Patients in two groups were treated for three months. After treatment, the clinical efficacy, liver function, and quality of life scores, liver fibrosis indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.40% and 95.35%, respectively, and there was difference between two groups (P < 0.05). After treatment, the ALT, AST, and TBIL levels in two groups significantly decreased, but PTA level was increased, and the difference was statistically significant in the same group (P < 0.05). And these liver function indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the somatic, psychological and social function, and material life score in two groups significantly increased (P < 0.05). And the quality of life scores in treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the HA, LN, PC-III and IV-C in two groups were significantly decreased (P < 0.05). And the decreased degree of these liver fibrosis indexes in treatment group was significantly better than that in the control group (P < 0.05). Conclusion Yunzhijun Capsules combined with Diammonium Glycyrrhizinate Capsules has significant effect in treatment of viral hepatitis, can significantly improve the quality of life, liver function and liver fibrosis index, which has a certain clinical application value.